Amneal Pharmaceuticals Inc (AMRX)
NASDAQ:AMRX
Want to see AMRX full AI Analyst Report?
AMRX Stock Chart & Stats
$13.91
$0.07(0.89%)
At close: 4:00 PM EST
$13.91
$0.07(0.89%)
Day’s Range― - ―
52-Week Range$7.02 - $15.42
Previous CloseN/A
Volume380.73K
Average Volume (3M)1.85M
Market Cap
$4.09B
Enterprise Value$6.51B
Total Cash (Recent Filing)$310.87M
Total Debt (Recent Filing)$2.74B
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 12, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding318,999,020
10 Day Avg. Volume1,393,991
30 Day Avg. Volume1,846,768
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)-55.77
Price to Sales (P/S)1.31
P/FCF Ratio14.63
Enterprise Value/Market Cap1.59
Enterprise Value/Revenue2.16
Enterprise Value/Gross Profit5.85
Enterprise Value/Ebitda10.78
Forecast
1Y Price Target
$17.25Price Target Upside24.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.99
Revenue Forecast (FY)$3.10B
Bulls Say, Bears Say
Bulls Say
Crexont Adoption And Market ShareAnalyst highlights strong early adoption and better patient persistence for Crexont versus the leading branded alternative, suggesting it could substantially increase market share and become a major revenue contributor.
Generics And Biosimilars PipelineAnalyst cites a broad generics and biosimilars pipeline and a strategic shift toward complex products that could support repeated new-product-driven growth and enable margin expansion.
Specialty Brand LaunchesAnalyst expects new specialty brand launches, including Parkinson's-focused products, to drive top-line growth and improve the company's product mix.
Bears Say
Authorized Generic CompetitionAnalyst warns that sales erosion of an older Parkinson's therapy from authorized generics could offset gains from new brands if uptake proves weaker than expected, pressuring overall revenue.
Low-margin Distribution ErosionAnalyst notes pressure from erosion of low-margin distribution sales at AvKARE, which is reducing segment revenues and weighing on company profitability.
Single-product CompetitivenessAnalyst cautions that a temporary revenue lift from a single product may decline as incoming competition arrives, creating near-term headwinds that generics growth may only partially offset.
Amneal Pharmaceuticals News
AMRX FAQ
What was Amneal Pharmaceuticals Inc’s price range in the past 12 months?
Amneal Pharmaceuticals Inc lowest stock price was $7.02 and its highest was $15.42 in the past 12 months.
What is Amneal Pharmaceuticals Inc’s market cap?
Amneal Pharmaceuticals Inc’s market cap is $4.09B.
When is Amneal Pharmaceuticals Inc’s upcoming earnings report date?
Amneal Pharmaceuticals Inc’s upcoming earnings report date is Aug 12, 2026 which is in 101 days.
How were Amneal Pharmaceuticals Inc’s earnings last quarter?
Amneal Pharmaceuticals Inc released its earnings results on May 01, 2026. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.169 by $0.101.
Is Amneal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amneal Pharmaceuticals Inc’s price is currently Undervalued.
Does Amneal Pharmaceuticals Inc pay dividends?
Amneal Pharmaceuticals Inc does not currently pay dividends.
What is Amneal Pharmaceuticals Inc’s EPS estimate?
Amneal Pharmaceuticals Inc’s EPS estimate is 0.23.
How many shares outstanding does Amneal Pharmaceuticals Inc have?
Amneal Pharmaceuticals Inc has 318,999,020 shares outstanding.
What happened to Amneal Pharmaceuticals Inc’s price movement after its last earnings report?
Amneal Pharmaceuticals Inc reported an EPS of $0.27 in its last earnings report, beating expectations of $0.169. Following the earnings report the stock price went down -0.311%.
Which hedge fund is a major shareholder of Amneal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amneal Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.25 (24.01% Upside)
$17.25 (24.01% Upside)
Blogger Sentiment
Bullish
AMRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 90.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.99%
12-Months-Change
Fundamentals
Return on Equity
-67.91%
Trailing 12-Months
Asset Growth
5.05%
Trailing 12-Months
Company Description
Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
AMRX Company Deck
AMRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted a decisive strategic move — the Kashiv acquisition — that meaningfully expands Amneal's addressable market, vertical capabilities, and long‑term growth runway in biosimilars. Q1 results showed strong top‑ and bottom‑line execution (revenues +4%, adjusted EBITDA +19%, adjusted EPS +29%), margin expansion, specialty product momentum, and improving leverage. Near‑term challenges include transaction‑related cash/financing impacts, modest near‑term dilution and guidance cadence (some 2027 EBITDA conservatism), integration and execution risk inherent to complex biologics development, and required CapEx to scale capacity. On balance, the positives around scale, pipeline, synergies ($400M–$500M), and improved long‑term financial trajectory outweigh the short‑term costs and execution risks.View all AMRX earnings summariesAMRX Stock 12 Month Forecast
Average Price Target
$17.25
▲(24.01% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Alvotech
―
Ownership Overview
17.07% Insiders
11.08% Mutual Funds
1.56% Other Institutional Investors
55.29% Public Companies and
Individual Investors